Skip to main content

Table 1 Comparative demographics of patients with MG and controls

From: Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Characteristics MGFA Classification Control
I II III IV-V  
NO. of samples(n) 58 30 24 13 50
Age (years) 46.10 ± 9.45 43.80 ± 10.83 45.63 ± 10.94 48.23 ± 9.65 46.14 ± 9.89
Female n (%) 28 (48.3) 15 (50.0) 10 (54.2) 5 (45.5) 26 (52.0)
AChR Ab pos n (%) 42 (72.4) 20 (66.7) 17 (70.8) 7 (53.8) NA
MuSK Ab pos n (%) 3 (5.2) 3 (10.0) 4 (16.7) 5 (38.5) NA
Double negative n (%) 13 (22.4) 7 (23.3) 3 (12.5) 1 (7.7)  
Treatment Pyridostigmine, 23 of 58 added oral Prednisone Pyridostigmine, 25 of 28 added oral Prednisone Pyridostigmine, IVIG, Subsequent oral prednisone Pyridostigmine, IVIG,
IV methylprednisolone
NA
  1. MG myasthenia gravis, AChR Ab acetylcholine receptor antibody, MuSK Ab muscle-specific tyrosine kinase antibody, I to V according to Myasthenia Gravis Foundation of America (MGFA) clinical classification; NA not available